Article

IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells.

Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1201, USA.
Journla of Immunotherapy (impact factor: 3.27). 29(3):313-9. DOI:10.1097/01.cji.0000210386.55951.c2 pp.313-9
Source: PubMed

ABSTRACT Lymphopenia is a serious consequence of HIV infection and the administration of cancer chemotherapeutic agents. Although growth factors can be administered to patients to increase circulating neutrophils, there is no effective method to stimulate CD8+ lymphocyte production in humans, in vivo. This report is the first to describe the administration of recombinant interleukin-7 to humans and demonstrates the ability of this cytokine to mediate selective increases in CD4+ and CD8+ lymphocytes along with a decrease in the percentage of CD4+ T-regulatory cells. These studies suggest an important role for interleukin-7 in the treatment of patients with lymphopenia.

0 0
 · 
0 Bookmarks
 · 
17 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

CD4+ T-regulatory cells
 
CD8+ lymphocytes
 
cytokine
 
decrease
 
effective method
 
growth factors
 
HIV infection
 
humans
 
Lymphopenia
 
patients
 
selective increases
 
serious consequence
 
stimulate CD8+ lymphocyte production
 
vivo